Compound profiles

Approved drug

Approved drug (somewhere, for at least one use)

• PT-141Libido · Approved in the US for one use
• SemaglutideGLP-1 / incretin · Approved; generics in Canada since 2026
• SS-31Mitochondrial · Approved for Barth syndrome (US)
• TesamorelinGH secretagogue · Approved for a specific use (US)
• Thymosin Alpha-1Immune · Approved in some countries; not Canada or US
• TirzepatideGLP-1 / incretin · Approved (Canada and US)

Large human trials

Large human trials, not yet approved

• CagrilintideAmylin analog · In trials; not approved
• RetatrutideGLP-1 / incretin · Phase 3 complete; not approved

Small human studies

Small or older human studies

• AOD-9604Fat loss (GH fragment) · Failed obesity trials; not approved
• CJC-1295 (with DAC)GH secretagogue · Not approved; development stopped
• GHK-CuSkin · Cosmetic ingredient; injection not approved
• IpamorelinGH secretagogue · Not approved; FDA Category 2
• Kisspeptin-10Hormonal · Research only; FDA Category 2
• NAD+Metabolic · Not approved as an injection
• SelankNootropic · Approved in Russia; not Canada or US
• SemaxNootropic · Approved in Russia; not Canada or US
• SermorelinGH secretagogue · Formerly approved; discontinued

Mostly animal studies

Mostly animal and lab studies

• BPC-157Healing · Not approved; mostly animal data
• BPC-157/TB-500 blendHealing (blend) · Not approved; no combination data
• EpitalonLongevity · Not approved; low-quality evidence
• KPVAnti-inflammatory · Not approved; lab and animal data
• MOTS-cMitochondrial · Not approved; mostly animal data
• TB-500Healing · Not approved; no controlled human trials

User reports only

No published human trials; user reports only

• CJC-1295 (no DAC)GH secretagogue · Not approved; no published human trials

Tools and guides

• Dose calculatorStrength, volume and syringe units for a dose you already have
• GuidesSyringe units, concentration, research-use products and fasting